Business Model

Emiliem’s Business Model is a “cost-contained innovation” model, which produces novel oncology therapeutics at a substantially reduced cost within an accelerated timeline and early feedback on mechanistic relevance. Emiliem welcomes inquiries on potential collaborations or out-licensing opportunities. Collaborations are envisioned to start from the beginning of profile lead series design or a later point based on the Company’s specific five milestone process: (1) confirmation of multi-kinase selectivity, (2) proof-of-concept in a cancer animal model, (3) selection of a development candidate for IND enabling work, (4) IND filed, and (5) proof-of concept clinical trial in targeted cancer patients.